不同氮源及CO_2浓度下湖泊微拟球藻的生长及产油特性分析

<正>工业生产排放的各种废气与污水污染人类赖以生存的环境。化石燃料燃烧除排放出大量CO2外,还释放出含有粉尘、SO[x和NOx等直接危害人类健康的有毒成分1]。其中NO]x与水结合后最终会转化成硝酸盐或亚硝酸盐等[2,导致污水中的含氮化合物氨氮、亚硝酸盐氮、硝酸盐氮和有机氮的含量通常偏高。如何有效去除污水中的氮是防治水体污染最关键的步骤之一,而利用微藻培养去除水体中的氮源是目前研究的热点。尽管生物燃料生产的成本远     

微生物1,3-1,4-β-葡聚糖酶蛋白质改造及工业应用研究进展

1,3-1,4-β-葡聚糖酶(E.C.3.2.1.73)是一种重要的工业用酶,其可以通过特异性切割毗邻β-1,3-糖苷键的β-1,4-糖苷键将β-葡聚糖或地衣多糖降解为纤维三糖和纤维四糖。微生物β-葡聚糖酶属于糖苷水解酶家族16,其三维结构为卷心蛋糕状的逆向β-片层结构。文中综述了近些年来β-葡聚糖酶在工业上的应用情况及酶蛋白质工程改造的研究进展,并对其研究前景进行了展望。     

柱前衍生-RP-HPLC法测定青蒿中青蒿素的含量

采用柱前衍生-RP-HPLC法测定10个不同产地的青蒿药材中青蒿素的含量.采用Lichrospher 100 RP-18e(250 mm×4.6 mm,5μm,Merck KgaA,Germany)色谱柱,甲醇-0.01 mol/L醋酸钠-醋酸缓冲液(pH 5.8)(体积比62:38)为流动相;检测波长:260 nm;流速:0.5 mL/min;柱温:25℃.结果表明该法准确重现性好,可以为青蒿质量标准的制订提供科学依据.     

栓皮栎林的生物量

本文对北京西山海拔300米的26年生人工栓皮栎林的生物量作了测定。粮据十株伐倒的标准木分别取得乔木各部分的干重。采用W=a(D2H)b的幂函数方程,获得每公顷土地上的树干重32.16吨,枝条重9.85吨、叶重1.68吨、根重9.95吨。对灌木和草本植物采用收割法作测定：灌木的地上部分每公顷为1.33吨,地下部分为2.3吨;草本植物的地上部分每公顷为0.15吨,地下部分为0.8吨。所以栓皮栎的地上部分总生物量每公顷为45.17吨,地下部分13.05吨,总计58.22吨。     

非损伤微测技术在植物根系生长发育研究中的应用

进出组织和细胞的无机离子的运输对植物生命极为重要。膜片钳和荧光成像等传统方法技术要求高、设备要求先进且测得的数据很难直接用于样品植株上。"非损伤微测技术"因其具有非损伤性、高的时空分辨率的特点,使其可以在不破坏样品的前提下测到样品的生理特征和生命活动规律,测得的数据生理真实性高,可以直接应用于样品植株上。文章较详细地介绍了运用非损伤微测技术,尤其是用于测量离子流的SIET技术和MIFE技术,及其在测量植物根部净离子流量以研究植物根系生长发育的一些报告。     

中华按蚊CYP6Y亚家族基因的鉴定和生物信息学分析

【目的】鉴定中华按蚊Anopheles sinensis CYP6Y亚家族基因,分析它们的结构和特征,推测其可能的功能。【方法】以冈比亚按蚊An. gambiae CYP6Y1作为询问序列,通过双向Blast方法检索中华按蚊转录组中CYP6Y亚家族基因,并通过生物信息学方法分析基因结构、特征及可能的功能。【结果】从中华按蚊转录组测序数据中鉴定出2条CYP6Y亚家族基因,分别命名为AsCYP6Y1（GenBank登录号：KF709397）和AsCYP6Y2（GenBank登录号：KF709398）。序列分析显示,AsCYP6Y1和AsCYP6Y2全长分别为1 713 bp和1 815 bp,分别编码502和526个氨基酸。基因结构分析显示,该亚家族基因仅含有1个相位1型内含子并与其他P450基因形成保守的共线性分布。蛋白结构分析显示,这2个基因编码的蛋白含P450特有的5个特征序列和6个底物结合位点,且均不存在信号肽,其亚细胞定位为细胞质。3D结构分析显示,AsCYP6Y1有18条α螺旋和13股反向平行的β折叠,AsCYP6Y2有19条α螺旋和11股反向平行的β折叠。通过同样的方法,在达林按蚊An. darlingi中也鉴定出2个CYP6Y亚家族基因。系统进化分析显示,AsCYP6Y1和AsCYP6Y2分别与其他3种按蚊的CYP6Y1和CYP6Y2聚成一支,Bootstrap值均大于90%。替换率分析显示,中华按蚊AsCYP6Y1和AsCYP6Y2与其他3种按蚊同源基因的Ka/Ks均小于1。相对进化速率分析显示,中华按蚊CYP6Y和CYP6M亚家族的相对进化速率均显著快于CYP6P亚家族,而CYP6Y和CYP6M亚家族之间没有显著差异。【结论】在中华按蚊和达林按蚊中存在2个CYP6Y亚家族基因,之前在冈比亚按蚊和不吉按蚊An. funestus中也发现2个CYP6Y亚家族基因,表明CYP6Y亚家族基因可能在按蚊属广泛存在,且可能为按蚊属昆虫所特有。     

植物转基因位置依赖性沉默与位置效应

植物基因组能够识别外源基因的出现及所整合的特异位置并产生相应反应,通过分析嘧啶甲基化的信号及模式,比较不同表达水平转基因的整合位点及基因组环境差异,植物转基因位置依赖性沉默和位置效应的机理得到进一步揭示;讨论了位置效应的研究方法和克服策略。     

Engineering imaging probes and molecular machines for nanomedicine

Nanomedicine is an emerging field that integrates nanotechnology, biomolecular engineering, life sciences and medicine; it is expected to produce major breakthroughs in medical diagnostics and therapeutics. Due to the size-compatibility of nano-scale structures and devices with proteins and nucleic acids, the design, synthesis and application of nanoprobes, nanocarriers and nanomachines provide unprecedented opportunities for achieving a better control of biological processes, and drastic improvements in disease detection, therapy, and prevention. Recent advances in nanomedicine include the development of functional nanoparticle based molecular imaging probes, nano-structured materials as drug/gene carriers for in vivo delivery, and engineered molecular machines for treating single-gene disorders. This review focuses on the development of molecular imaging probes and engineered nucleases for nanomedicine, including quantum dot bioconjugates, quantum dot-fluorescent protein FRET probes, molecular beacons, magnetic and gold nanoparticle based imaging contrast agents, and the design and validation of zinc finger nucleases (ZFNs) and TAL effector nucleases (TALENs) for gene targeting. The challenges in translating nanomedicine approaches to clinical applications are discussed.     

Inhibition of mitochondrial complex I improves glucose metabolism independently of AMPK activation

Accumulating evidences showed metformin and berberine, well‐known glucose‐lowering agents, were able to inhibit mitochondrial electron transport chain at complex I. In this study, we aimed to explore the antihyperglycaemic effect of complex I inhibition. Rotenone, amobarbital and gene silence of NDUFA13 were used to inhibit complex I. Intraperitoneal glucose tolerance test and insulin tolerance test were performed in db/db mice. Lactate release and glucose consumption were measured to investigate glucose metabolism in HepG2 hepatocytes and C2C12 myotubes. Glucose output was measured in primary hepatocytes. Compound C and adenoviruses expressing dominant negative AMP‐activated protein kinase (AMPK) α1/2 were exploited to inactivate AMPK pathway. Cellular NAD⁺/NADH ratio was assayed to evaluate energy transforming and redox state. Rotenone ameliorated hyperglycaemia and insulin resistance in db/db mice. It induced glucose consumption and glycolysis and reduced hepatic glucose output. Rotenone also activated AMPK. Furthermore, it remained effective with AMPK inactivation. The enhanced glycolysis and repressed gluconeogenesis correlated with a reduction in cellular NAD⁺/NADH ratio, which resulted from complex I suppression. Amobarbital, another representative complex I inhibitor, stimulated glucose consumption and decreased hepatic glucose output in vitro, too. Similar changes were observed while expression of NDUFA13, a subunit of complex I, was knocked down with gene silencing. These findings reveal mitochondrial complex I emerges as a key drug target for diabetes treatment. Inhibition of complex I improves glucose homoeostasis via non‐AMPK pathway, which may relate to the suppression of the cellular NAD⁺/NADH ratio.